Contracts Finder

NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025

NHS England

Awarded
goods
SME-friendly
Framework agreement

Published on NHS Health Family Atamis procurement portal

This tender has closed

The submission deadline for this contract has passed. There may be more active goods tenders from NHS England, and hundreds more across the UK public sector.

Key details

Contracting authority
NHS England
nhs
Region
Runcorn
Delivery: United Kingdom
Sector
Healthcare & Medical
Contract value
£4,108,145,000ex VAT
Submissions closed
7 April 2025
Published
17 February 2025

Procurement

Contract period
1 September 2025 - 31 August 2027
2 years
Procedure type
Open procedure (above threshold)
CPV classifications
  • 33600000 Pharmaceutical products

What happened

NHS England awarded this contract to Biogen | Amgen Ltd | Sobi (Swedish Orphan Biovitrum Ltd) | Zentiva Pharma UK Ltd | Fresenius Kabi Limited | Sandoz Ltd | Thornton and Ross Ltd | Roche Products Ltd | Accord-UK Ltd | GlaxoSmithKline UK Limited | Samsung Bioepis UK Ltd | Pfizer Ltd | Janssen-Cilag Ltd | Celltrion Healthcare United Kingdom Limited | Abbvie Ltd | Takeda UK Ltd | Organon Pharmaceuticals UK Ltd | Alexion Pharmaceuticals | Orifarm UK | CuraTeQ Biologics s.r.o. | Dr.Reddy's Laboratories (UK) Limited worth £986,282,758 on 1 Jul 2025. The contract runs until 31 Aug 2027.

Description

NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

Awarded suppliers (21)

Suppliers
  • Biogen
  • Amgen Ltd
  • Sobi (Swedish Orphan Biovitrum Ltd)
  • Zentiva Pharma UK Ltd
  • Fresenius Kabi Limited
  • Sandoz Ltd
  • Thornton and Ross Ltd
  • Roche Products Ltd
  • Accord-UK Ltd
  • GlaxoSmithKline UK Limited
  • Samsung Bioepis UK Ltd
  • Pfizer Ltd
  • Janssen-Cilag Ltd
  • Celltrion Healthcare United Kingdom Limited
  • Abbvie Ltd
  • Takeda UK Ltd
  • Organon Pharmaceuticals UK Ltd
  • Alexion Pharmaceuticals
  • Orifarm UK
  • CuraTeQ Biologics s.r.o.
  • Dr.Reddy's Laboratories (UK) Limited
Award value
£986,282,758
Award date
1 July 2025

Contact

Address
2nd Floor, Rutland House, Runcorn, WA7 2ES
Website
https://health-family.force.com/s/Welcome
Contact name
Lynne Tierney
Email
[email protected]

Identifiers

Buyer reference
CF-3097700D0O000000rwimUAA
Notice ID
cc644418-f584-45db-bf35-771baf03bc48-856590
OCID
ocds-b5fd17-04aa1520-7ead-4f1f-bebb-422062580323

Explore related tenders

Other tenders from NHS England

View all →
Secondary Care Medicines Data Pre-Market Engagement£6,750,000
Quality Assurance & Improvement of Structured Learning Placement (SLP) Modules£98,000
Targeted Prostate Cancer Screening Programme - MRI Reporting Service
Targeted Prostate Cancer Screening Programme – PSA Laboratory Processing Service
Strengthening Cultural Capability and Trauma Informed Care in Women’s Health£175,000

External ID: cf-ocds-b5fd17-04aa1520-7ead-4f1f-bebb-422062580323 • Added 3 October 2026